key: cord-0956622-tqkyp9ay
authors: Li, Ang; Kuderer, Nicole M.; Hsu, Chih‐Yuan; Shyr, Yu; Warner, Jeremy L.; Shah, Dimpy P.; Kumar, Vaibhav; Shah, Surbhi; Kulkarni, Amit A.; Fu, Julie; Gulati, Shuchi; Zon, Rebecca L.; Li, Monica; Desai, Aakash; Egan, Pamela C.; Bakouny, Ziad; KC, Devendra; Hwang, Clara; Akpan, Imo J.; McKay, Rana R.; Girard, Jennifer; Schmidt, Andrew L.; Halmos, Balazs; Thompson, Michael A.; Patel, Jaymin M.; Pennell, Nathan A.; Peters, Solange; Elshoury, Amro; de Lima Lopes, Gilbero; Stover, Daniel G.; Grivas, Petros; Rini, Brian I.; Painter, Corrie A.; Mishra, Sanjay; Connors, Jean M.; Lyman, Gary H.; Rosovsky, Rachel P.
title: The CoVID‐TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID‐19
date: 2021-08-13
journal: J Thromb Haemost
DOI: 10.1111/jth.15463
sha: 00138206f26ff2304a44c6caad638fb26a254252
doc_id: 956622
cord_uid: tqkyp9ay

BACKGROUND: Hospitalized patients with COVID‐19 have increased risks of venous (VTE) and arterial thromboembolism (ATE). Active cancer diagnosis and treatment are well‐known risk factors; however, a risk assessment model (RAM) for VTE in patients with both cancer and COVID‐19 is lacking. OBJECTIVES: To assess the incidence of and risk factors for thrombosis in hospitalized patients with cancer and COVID‐19. METHODS: Among patients with cancer in the COVID‐19 and Cancer Consortium registry (CCC19) cohort study, we assessed the incidence of VTE and ATE within 90 days of COVID‐19–associated hospitalization. A multivariable logistic regression model specifically for VTE was built using a priori determined clinical risk factors. A simplified RAM was derived and internally validated using bootstrap. RESULTS: From March 17, 2020 to November 30, 2020, 2804 hospitalized patients were analyzed. The incidence of VTE and ATE was 7.6% and 3.9%, respectively. The incidence of VTE, but not ATE, was higher in patients receiving recent anti‐cancer therapy. A simplified RAM for VTE was derived and named CoVID‐TE (Cancer subtype high to very‐high risk by original Khorana score +1, VTE history +2, ICU admission +2, D‐dimer elevation +1, recent systemic anti‐cancer Therapy +1, and non‐Hispanic Ethnicity +1). The RAM stratified patients into two cohorts (low‐risk, 0–2 points, n = 1423 vs. high‐risk, 3+ points, n = 1034) where VTE occurred in 4.1% low‐risk and 11.3% high‐risk patients (c statistic 0.67, 95% confidence interval 0.63–0.71). The RAM performed similarly well in subgroups of patients not on anticoagulant prior to admission and moderately ill patients not requiring direct ICU admission. CONCLUSIONS: Hospitalized patients with cancer and COVID‐19 have elevated thrombotic risks. The CoVID‐TE RAM for VTE prediction may help real‐time data‐driven decisions in this vulnerable population.

Numerous studies have demonstrated a complex interplay between inflammation and coagulation associated with COVID-19 that results in an increased risk of venous thromboembolism (VTE) and arterial thrombotic events (ATE). [1] [2] [3] [4] Specifically, the exact incidence of VTE associated with COVID-19 is debated and has ranged from as low as 1% in the general wards to as high as 69% in intensive care units (ICUs) in published reports, depending on the diagnostic approach used and whether screening was performed. 5, 6 The link between coagulopathy and COVID-19 has led to an international collaborative effort of randomized controlled studies designed to investigate the use of anticoagulant therapy to prevent complications associated with COVID-19 among hospitalized medical inpatients, of which the interim unpublished results were recently released. 7 Both cancer and anti-cancer therapies are well-known risk factors for thrombotic events. 8, 9 While many risk factors have been identified for VTE in patients with cancer, advanced disease as well as certain cancer types such as neoplasms of the pancreas, esophagus, and stomach carry the highest risk. 10, 11 Moreover, patients with cancer have a higher incidence of VTE compared to acutely ill medical patients without cancer. 12, 13 Despite being a well-known phenotype for thrombosis, cancer diagnosis and anti-cancer therapy

have not yet been identified as a strong risk factor for COVID-19associated thrombosis and the exact thrombotic risk in hospitalized patients with both cancer and COVID-19 remains unknown. In addition, patients with cancer not only have a higher risk of VTE but also have a higher risk of bleeding on anticoagulation compared to patients without cancer. 14, 15 A better understanding of the epidemiology and risk factors of thrombosis in patients with cancer and COVID-19 will also help researchers, clinicians, and policymakers to place results from the beforementioned randomized controlled trials in a relevant context and help discuss appropriate thromboprophylaxis in more vulnerable patients.

The current study has two aims. First, we aim to estimate the 90-day incidence of VTE and ATE for patients with COVID-19 and cancer requiring hospitalization, stratified by ICU status and active cancer status. Second, we aim to derive a simple risk assessment model (RAM) specifically for VTE at the time of hospital admission.

The COVID-19 and Cancer Consortium registry (CCC19; NCT04354701) is an ongoing multi-center effort to assess the clinical-pathologic factors and disease course among patients with COVID-19 and either a current or previous diagnosis of cancer.

Details of the original study design and data capture have been reported previously and are available publicly. [16] [17] [18] Briefly, data were captured at baseline around the time of COVID-19 diagnosis and then at 30 days, 90 days, and 180 days after diagnosis. Centralized data management is coordinated through REDCap at Vanderbilt University. Given the de-identified nature of the data collected, this study has been exempted from institutional review board (IRB) review at Vanderbilt University.

Adult patients with an active or previous diagnosis of cancer with a laboratory-confirmed SARS-CoV-2 test from March 17, 2020 to November 30, 2020 were included in the current study. Patients were excluded if they did not reside within United States or Canada, did not have assessable thrombotic complication status within 90 days (13 weeks), were never hospitalized at baseline, had poor data quality (quality score ≥5, typically due to very high levels of missingness), 19 or had follow-up less than 30 days (interval between the COVID-19 diagnosis and the analysis data lock).

The primary outcomes included VTE as defined by pulmonary embolism (PE), deep vein thrombosis (DVT), or thrombosis not otherwise specified (NOS); and ATE as defined by myocardial infarction (MI) or ischemic stroke (CVA). Secondary outcomes included frequency of PE and/or DVT (excluding thrombosis NOS), PE only, or CVA only.

All thrombotic complications were captured as binary "yes/no" responses through retrospective chart review. The exact definition (imaging vs. clinical diagnosis, proximal vs. distal, symptomatic vs. incidental) was left to the discretion of individual sites. Notably, superficial venous thrombosis (SVT) was captured separately and was not included in any of the above definitions.

Members of the thrombosis research working group within the CCC19 defined important prognostic risk factors for VTE in hospitalized medical patients with both cancer and COVID-19 using previously published data from general medical inpatients, 20 patients with cancer, 10 and patients with COVID-19 5 (Table S1 in 

The cumulative incidence of VTE and ATE within 90 days after COVID-19-associated admission was determined by the number of reported VTE or ATE events from data forms within 13 weeks of follow-up divided by the number of total available patients that met the inclusion and exclusion criteria. The primary and secondary outcomes were further estimated in pre-specified subgroups (ICU vs. wards, recent systemic therapy vs. none). The incidence trend was also plotted over quarterly intervals for the year 2020.

As neither thrombotic nor mortality events had associated time stamps to protect patient identity, we did not perform competing risk analyses.

To derive a prognostic RAM for VTE, we built a multivariable logistic regression model to assess the association between 90-day VTE outcomes and baseline covariates. We included all pre-specified clinical covariates in a single model. With the exception of age, all other covariates were categorical. Age was explored both as a continuous linear variable and cubic splines. Additionally, interaction between age and other covariates was checked using the likelihood ratio test. Adjusted odds ratios (OR) and 95% confidence intervals (CI) for VTE and PE were estimated from the models. The relative strengths of each predictor within the model were assessed using the model chi-square statistic. Multiple imputation through 10 iterations with additive regression, bootstrapping, and predictive mean matching was used to impute missing/unknown data for all clinical variables with <5% missingness in the primary analysis or laboratory variables with <10% missingness in the sensitivity analysis.

To create a simplified RAM, we used the strongest predictors from the multivariable model and assigned simplified integer scores In the prespecified subgroup analysis ( There are 66 patients with unknown/missing recent anti-cancer status.

Within normal limit of normal 58% (1614)

Below lower limit of normal 20% (552)

Above higher limit of normal 17% (468)

Unknown/missing 10% (173)

Within normal limit of normal 37% (1034)

Below lower limit of normal 55% (1552)

Above higher limit of normal 2% (45) Unknown/missing 6% (173)

Within normal limit of normal 61% (1709)

Below lower limit of normal 27% (757)

Above higher limit of normal 4% (125) Unknown/missing 8% (213)

Within normal limit of normal 9% (247) 

We performed several additional scenario and sensitivity analyses. In the scenarios in which we retested the clinical model after excluding patients on anticoagulants prior to admission ( 

Based on the key predictors from the multivariable model, we created a simplified prediction score by assigning integer weights proportional to the beta coefficients. 

In this retrospective cohort study of 2804 hospitalized patients with COVID-19 and cancer, we found the 90-day VTE and ATE incidences were elevated at 7.6% (n = 213) and 3.9% (n = 109), respectively.

VTE risk was higher in patients admitted to ICU and those with active cancer having received recent systemic therapy. Our newly derived VTE risk assessment model, the CoVID-TE score, incorporated six clinicopathologic factors readily available at the time of hospital admission. With a modest discrimination, the CoVID-TE score stratified patients into two different risk categories: 58% in the low-risk group (score 0-2) had an observed incidence of 4.1% for VTE and 2.3% for PE; 42% in the high-risk group (score 3+) had an incidence of 11.3% for VTE and 5.5% for PE. Patients with these thrombotic risk factors might also be at higher risk for bleeding and mortality.

We believe risk stratification from the current study can provide relevant context and help with the interpretation and implementation of anticoagulant prophylaxis based on the results of ongoing randomized controlled trials for this vulnerable patient population.

While COVID-19, prolonged hospitalization, and active cancer are all well-known pro-thrombotic risk factors, the exact incidence of thrombosis in a population with all three has not been previously reported. We examined the incidence over a 90-day follow-up to match with previous studies for medical inpatient-associated thrombosis. 20 Among general patients hospitalized with COVID-19, the reported incidence based on retrospective cohort studies varies TA B L E 3 Simplified risk assessment model for VTE (CoVID-TE thromboembolism score) in hospitalized patients with complete data. (a) CoVID-TE score assignment, (b) CoVID-TE risk category stratification and performance

Cancer subtype by original Khorana score a +1 VTE history (lifetime) +2

ICU triage on admission +2

Therapy (recent systemic last 3 months) +1

Ethnicity non-Hispanic c +1

All hospitalized patients (n = 2457)

Low-risk (0-2) 4.1% (59) 2.3% (33) In contrast, those admitted to the ICU have a reported incidence of VTE ranging from 8% to 14% and ATE ranging from 6% to 8%. [22] [23] [24] [25] [26] In the current study, we observed a similar incidence of hospital- available to providers at the time of admission with the potential to impact the care of patients with cancer and COVID-19 in a meaningful way. Limitations inherent to our non-randomized retrospective study nature include the potential for unmeasured confounding, selection bias, and underreporting of outcomes. Given that each institution had its own protocol for the prevention and diagnosis of thrombosis, this heterogeneity could have impacted the actual rates from individual sites, although the stable aggregate rates of VTE over each quarter of 2020 verified overall consistency. Furthermore, the heterogeneous use of anticoagulation before admission (21%) and the low proportion of very high-risk cancer types (3%) may limit the generalizability of the RAM. Additionally, we did not perform timeto-event or competing risks analysis due to the lack of specific timing for VTE complications. Finally, for any novel model to be clinically applicable, it needs to be tested and validated in an external cohort.

In conclusion, we investigated the incidence of venous and arterial thromboses in hospitalized patients with cancer and COVID-19

and derived a new RAM that can be calculated at the time of admission to risk stratify patients into different VTE risk groups. We anticipate that the CoVID-TE RAM, upon external validation, can serve as a real-time clinical decision support tool to assist with personalized decisions on the initiation of thromboprophylaxis in hospitalized patients with cancer and COVID-19. 

Amgen (to institution); consulting for BeyondSpring, G1 Therapeutics, Samsung, TEVA, all outside the scope of the submitted work. GdLL reports honoraria from Boehringer Ingelheim; consulting or advisory role for Pfizer and AstraZeneca

travel, accommodations, and expenses from Boehringer Ingelheim, Pfizer, E.R. Squibb Sons, LLC, Janssen, all outside the scope of the submitted work. NMK reports personal fees from G1 Therapeutics

all outside the scope of the submitted work. JW reports research grant support from the National Cancer Institute in support of this work; the funder had no role in the design of conduct of the study, or the decision to publish

outside the scope of the submitted work. VK reports honoraria from

outside the scope of the submitted work. CAP (or an immediate family member) have currently or during the past 2 years owned stock or held an ownership interest in Pfizer, Epizyme, Inovio, OPKO Health Inc, Roche., all outside the scope of the submitted work. CH reports funding from the Henry Ford Cancer Institute supporting the current work; research funding paid to her institution from Merck

Tempus; is a consultant for Dendreon, Vividion; serves on the molecular tumor board at Caris, all unrelated to the current scope of work. SG reports research funding to the institution from Astra-Zeneca and consulting/ advisory role with Puma Biotechnology. MAT reports travel support from Syapse; royalties from UpToDate, Connect MDS/AML Registry in Celgene (now owned by BMS), Myeloma Registry in Takeda; stock ownership in Doximity; personal fees from VIA Oncology

Thompson is the Local PI for

ZB reports research support from Bristol-Myers Squibb and Genentech/imCORE; honoraria from UpToDate, all outside the scope of the submitted work. NAP reports honoraria for consulting/advisory boards: Merck

Novartis, Pfizer, Sanofi, (all fees to institution), outside the submitted work; PG (all unrelated to this study, in the last 3 years) has provided consulting or advisory services for AstraZeneca

Seattle Genetics, and 4D Pharma PLC; and has received research funding from Bavarian Nordic

JLW performed the statistical analysis. AL, RPR drafted the manuscript

Thrombosis and COVID-19 pneumonia: the clot thickens!

Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19

Endothelial cells orchestrate COVID-19 coagulopathy

Endothelial cell infection and endotheliitis in COVID-19

Risk of venous thromboembolism in patients with COVID-19: a systematic review and meta-analysis

Incidence of VTE and bleeding among hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis

Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients

Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study

Development and validation of a predictive model for chemotherapy-associated thrombosis

Cancer associated thrombosis and mortality in patients with cancer stratified by khorana score risk levels

Malignancies, prothrombotic mutations, and the risk of venous thrombosis

Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis

Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: a COVID-19 and cancer consortium (CCC19) cohort study

Association of clinical factors and recent anti-cancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and cancer consortium

COVID-19 and cancer consortium. a systematic framework to rapidly obtain data on patients with cancer and COVID-19: CCC19 governance, protocol, and quality assurance

Prognostic factors for VTE and bleeding in hospitalized medical patients: a systematic review and meta-analysis

Anticoagulation practice patterns in COVID-19: a global survey

Thrombosis in hospitalized patients with COVID-19 in a New York City health system

Clinical characteristics of Covid-19 in New York City

COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection

VTE in ICU patients With COVID-19

Thrombosis, bleeding, and the observational effect of early therapeutic anticoagulation on survival in critically Ill patients With COVID-19

Scientific and standardization committee communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19

A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts

The predictive approaches to treatment effect heterogeneity (PATH) statement: explanation and elaboration

The CoVID-TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID-19